BerGenBio

Environmental & Social Information • Mar 26, 2025

BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

The article identifies promising survival results in relapsed/refractory AML

patients

warranting further study

Bergen, Norway - 26 March 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, today announces the publication of a peer-reviewed article

entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine

in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the

journalNature Communications.

This article is accessible here: www.nature.com/articles/s41467-025-58179-6.pdf

The article highlights results in 36 patients treated with a combination of

BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low

-dose cytarabine(LDAC) chemotherapy. Overall, patients who received the

combination had an overall survival of 7.8 months, substantially longer than

that expected in this difficult-to-treat patient population.

The lead investigator of the study, Professor Sonja Loges, MD, PhD. of the

German Cancer Research Center (DKFZ), Heidelberg, Germany stated, "Following

first line treatment of AML, most patients will relapse, and beyond first line

the prognosis of older patients with relapsed or refractory AML, the population

studied in BGBC003 is particularly poor. With other treatment approaches, the

current overall survival of R/R AML patients is believed to be approximately 2.9

-4 months.  The authors of this article believe that the BGBC003 results in this

population warrant further study."

Olav Hellebo, CEO of BerGenBio commented "Our BGBC003 study evaluated

bemcentinib in relapsed/refractory (R/R) AML patients who have limited effective

treatment options today.  The presence of AXL is a poor prognostic factor in

this population and AXL is believed to promote chemotherapy resistance and

decreased antitumor immune response.  We believe, as a highly selective AXL

inhibitor, bemcentinib holds promise as a treatment for these patients with

extremely high unmet medical needs."

Contacts

Olav Hellebo, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with

a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.